Compare Moderna, Inc. (MRNA) vs Micron Technology, Inc. (MU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Micron Technology, Inc. — how do they compare? Moderna, Inc. trades at $136.5 (market cap $54.14B), while Micron Technology, Inc. trades at $1,011.97 (market cap $1.16T). The key difference: Micron Technology, Inc. is far larger — about 21.4× Moderna, Inc.'s market cap, and Micron Technology, Inc. pays a 0.05% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | MU | |
|---|---|---|
Market Cap | $54.14B | $1.16T |
Sector | Health | Technology |
52-Week High | $174.38 | $1.21K |
52-Week Low | $22.36 | $140.00 |
Enterprise Value | $50.29B | $1.14T |
Dividend Yield | — | 0.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $140.33, down 3.59% on the day, amid mixed signals. The stock has seen volatility, with a 143% surge over the past month driven by positive cancer vaccine trial results (Fox Business, 2026-09-06), but faces headwinds from declining revenue and persistent net losses. Technical analysis shows a bullish overall signal, with support at $138 and resistance at $145, while fundamentals reveal a challenging profit margin of -142.58% for 2026.
The outlook hinges on pipeline successes, particularly in oncology, but high valuation ratios and competitive pressures pose risks. Analyst consensus is cautious, with a $90.08 price target, reflecting skepticism despite recent clinical milestones. Investors should weigh innovation potential against financial sustainability and market sentiment shifts.
Micron Technology (MU) trades at $1,000.26, down 1.61% today but remains in a strong uptrend, supported by bullish technical signals and robust fundamentals. The company reported Q1 2026 EPS of $25.11, beating estimates by 20%, with revenue surging to $37.38 billion in 2025. Operating cash flow hit $17.53 billion, while analyst consensus is strongly bullish with an 82.9% buy rating and a $1,550 price target.
Outlook is positive due to AI-driven memory demand, with 2026 revenue projected at $90.3 billion. Risks include memory market cyclicality and supply constraints, but Micron's margin expansion and institutional support suggest further upside for investors seeking growth in semiconductor equities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Micron Technology, Inc.
Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.
Read more on MU →
